Better Therapeutics
Biotechnology ResearchCalifornia, United States2-10 Employees
Better Therapeutics is a biotechnology research company headquartered in San Francisco, California, that operates as a fully distributed organization with remote work complemented by periodic in-person meetings; its workforce comprises 2–10 employees located in 18 states. The company develops prescription digital therapeutics that deliver behavioral therapy to patients, with an initial focus on cardiometabolic diseases, beginning with type 2 diabetes. Better Therapeutics went public via a merger with Mountain Crest Acquisition Corp. (Nasdaq: MCAD) in fall 2021. AspyreRx, the company's digital therapeutic for type 2 diabetes, was launched in October 2023, and in 2024 the company pursued regulatory recognition and partnerships, including FDA Breakthrough Device Designation for its CBT platform addressing metabolic dysfunction-associated steatohepatitis. Recent activities include an integration with Glooko announced in January 2024, a collaboration with the American College of Lifestyle Medicine to expand AspyreRx access across 1,400 Federally Qualified Health Centers, and the sale of assets to Click Therapeutics in May 2024.
1-888-653-2347 
support@leadiq.com 
